Wells Fargo raised the firm’s price target on Abbott (ABT) to $146 from $142 and keeps an Overweight rating on the shares. The firm notes the company reported about in-line Q3 sales and EPS on Nutrition and China Dx headwinds, offset by Medtech and EPD strength. Abbott reiterated 2025 organic sales growth and tightened its EPS guide. The company is comfortable with prior 2026 Street estimates, Wells adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott Laboratories: Strong Growth Prospects and Stable Financial Health Drive Buy Rating
- Abbott Laboratories Reports Strong Q3 2025 Earnings
- Abbott Laboratories’ Earnings Call Highlights Strong Growth
- Strong Performance and Future Potential: Buy Rating for Abbott Laboratories
- Promising Growth Prospects for Abbott Laboratories Amid Short-term Challenges: A Buy Rating by Brandon Vazquez